HeartSciences (NASDAQ:HSCS) Trading Down 1.4% – Time to Sell?

HeartSciences Inc. (NASDAQ:HSCS)’s stock price fell 1.4% on Wednesday . The stock traded as low as $2.0050 and last traded at $2.04. 19,167 shares were traded during mid-day trading, a decline of 43% from the average session volume of 33,735 shares. The stock had previously closed at $2.07.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HSCS. Ascendiant Capital Markets cut their price target on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

HeartSciences Trading Down 1.4%

The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 1.04. The firm has a market capitalization of $6.49 million, a PE ratio of -0.41 and a beta of 1.96. The company’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $2.58.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.21. As a group, sell-side analysts expect that HeartSciences Inc. will post -3.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On HeartSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HSCS. Geode Capital Management LLC acquired a new position in shares of HeartSciences during the second quarter valued at approximately $43,000. TFB Advisors LLC acquired a new position in shares of HeartSciences during the third quarter valued at approximately $105,000. Finally, DRW Securities LLC raised its holdings in shares of HeartSciences by 13.7% during the fourth quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock valued at $294,000 after acquiring an additional 11,455 shares during the last quarter. 17.24% of the stock is owned by hedge funds and other institutional investors.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.